NIKKEI 225
38,287.96 +85.59 (+0.22%) HANG SENG
18,395.21 +81.35 (+0.44%) CRUDE OIL
79.32 +0.33 (+0.42%) GOLD FUTURES
2,318.80 -3.50 (-0.15%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,211.80 -821.33 (-1.64%)
MannKind Corporation (MNKD)
After hours:
| Previous close | 4.4700 |
| Open | 4.4700 |
| Bid | 4.3900 x 1000 |
| Ask | 4.4400 x 100 |
| Day's range | 4.3400 - 4.4800 |
| 52-week range | 3.1700 - 5.7500 |
| Volume | |
| Avg. volume | 2,958,040 |
| Market cap | 1.191B |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET)1Q 2024 Total revenues of $66M; +63% vs. 1Q 20231Q 2024 Net income of $11M; Non-GAAP net income of $15M$304M of cash and cash equivalents and investments at March 31, 2024In early April, repaid Midcap senior-secured debt and Mann Group convertible debt totaling approximately $37M FDA Fast Track designation and IND clearance received for MNKD-101 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasd
- GlobeNewswire
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation of Clofazimine Inhalation Suspension (MNKD-101) for the treatment of nontuberculous mycobacterial (NTM) lung disease.
- GlobeNewswire
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 8, 2024. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentat
